中文 | English
Return
Total: 6 , 1/1
Show Home Prev Next End page: GO
MeSH:(Cilastatin/therapeutic use)

1.Investigation on the antibiotic resistance and risky factors of nosocomial infections caused by Stenotrophomonas maltophilia.

Chao ZHUO ; Yuan-shu QIAN ; Guang-xia XIAO

Chinese Journal of Burns 2004;20(1):10-13

2.Clinical analysis of 29 children with early infectious complications following hematopoietic stem cells transplantation.

Yang LI ; Shao-liang HUANG ; Jian-pei FANG ; Dun-hua ZHOU ; Chun CHEN

Chinese Journal of Pediatrics 2003;41(7):520-524

3.Comparison of Efficacy of Cefoperazone/Sulbactam and Imipenem/Cilastatin for Treatment of Acinetobacter Bacteremia.

Jun Yong CHOI ; Chang Oh KIM ; Yoon Seon PARK ; Hee Jung YOON ; So Youn SHIN ; Young Keun KIM ; Myung Soo KIM ; Yeon A KIM ; Young Goo SONG ; Dongeun YONG ; Kyungwon LEE ; June Myung KIM

Yonsei Medical Journal 2006;47(1):63-69

4.Imipenem-cilastatin versus sulbactam-cefoperazone plus amikacin in the initial treatment of febrile neutropenic cancer patients.

Ozgur OZYILKAN ; Ulku YALCINTAS ; Sezgin BASKAN

The Korean Journal of Internal Medicine 1999;14(2):15-19

6.A randomized, controlled clinical trial on meropenem versus imipenem/cilastatin for the treatment of bacterial infections.

Fang HOU ; Jiatai LI ; Guoping WU ; Bo ZHENG ; Yifang CHEN ; Junming GU ; Huiling WANG ; Li HUO ; Xin XUE ; Changxu JIA ; Yonghong YIN ; Xiaofeng TIAN ; Shuangyi REN

Chinese Medical Journal 2002;115(12):1849-1854

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 6 , 1/1 Show Home Prev Next End page: GO